Susanne Schnittger. Workflow of molecular investigations in JAK2-negative MPNs - the Munich experience
|
|
|
- Eugene Reeves
- 5 years ago
- Views:
Transcription
1 Susanne Schnittger Workflow of molecular investigations in JAK2negative MPNs the Munich experience
2 Cohort single centre experience to apply new markers in a daily diagnostic work flow total: 20,547 cases with suspected MPN investigated between 8/2005 und 9/2012 individual patient specific combinations
3 Most frequently tested marker Applied in 17,763 pts Melting curve analysis with a sensitivity of 1% (d/dt) Fluorescence (640/530) 5% 1% 100%Mut 100% WT
4 In 6,622/17,027 (34%) being mutated a definite diagnosis of MPN could be made or confirmed
5 Coincidence of BCRABL1 and n= % BCRABL/JAK % BCRABL/JAK % BCRABL/JAK % BCRABL/JAK % ,00
6 JAK2 Exon12 Mutations H538QK539L WT H538DK539LI540S N542E543del Scott et al., NEJM, 2007 In 348 cases with negative PV/Polyglobuly JAK2exon12 mutation was analyzed 64/348 (18.3%) were tested positive
7 JAK2 Exon12 Mutationen 64/348 (18.3%) were tested positive 50% with isolated erythrocytoses in median 11 years younger than mutated PV (56 vs. 67 years, p=0.001) Females/Males: 2/1 (p=0.012)
8 JAK2 Exon12 Mutations Cohort: n=2,524 3, % 3,200 2,800 2,400 2,000 1,600 1, % positive negative % 0 n= 0/56 0/28 39/208 8/ /1651 0/12
9 MPLW515 Mutations WT MPLW515K MPLW515L Thrombopoietin Receptor Amino acid exchange: MPLW515 Pardanani et al., Blood 2006 /Pikman et al., PloS Medicine 2006
10 MPLW515 Mutations 294/6660 (4.4%) W515L, W515K, W515A, W515S und W515R (Tryptophan> Leucine, Lysin, Alanin, Serin, Arginin) positive negative ET PV PMF CMML MPNU MPN* unexplained thrombocytoses*
11 CBL Mutations CBL C404T/W/Y F418S I383M/T I393S H398A P417A/H R420L/Q L370_C271del C384T D390V/Y G397V C416R/S/Y I423N V430M Q367L I375C Q379A L380G/P D388G C396Y C403Y W408C/L G415S C419Y I429F/N
12 CBL Mutations in different Entities Total: 53/636 (9.9%) cases 26/199 CMML (13.0%) 1/25 PMF (4.0%) 27/293 MPNU (9.2%) % % CBL mutated CBL wt % 0
13 Coincidence of other mutations with CBL
14 Results of Mutation Analysis Exon Exon11 AA BOX1 BOX2 L18X Q108L C237X L34F A118LfsX10 C133WfsX11 L144X P174H G355B P516QfsX23 Q674X K753RfsX14 Q916X P1012L M1164I G1256R L1362P L1531HfsX40 V1718L H1778LfsX42 Trp1917GlyfsX33 Gln440X R544X Q675X N861TfsX11 C973X R1176GfsX50 S1369X Q1539SfsX32 V1723S L1819X N861TfsX12 N1296D A1434SfxX45 R1739I G1861R S460F L615AfsX23 S735R S1023HfsX3 C1193S N1299X Q1557CfsX21 I1873T Y867H Q939X K1038DfsX16 L1199FfsX19 F1585S E1874K E885X Q1084P C1211Y A1341 H1893P Glu885X Q1084PfsX19 L1212S D1376G R1216X T940PfsX13 L1101PfsX29 N1266S I1105RfsX23 C1271W F1287LfsX76 F1287S C1289W S1290X
15 Mutations according to Diagnosis 338/738 (45.8%) 77.4% 19.8% mutated 21.4% 32.3% wt 33.3% 11.1% 33.3%
16 Association of other mutations with % % % 3.6% 1.8% 1.8% 3.6% 0 n =
17 EZH2 Mutations Ernst et al., Nature Genetics, 2010 Exon D1 D2 CXC SET Q103G Q109R Y124C M125T K147E G150E A217V N351X R488Q E361TfsX29 D650N R676H N679S H680R
18 EZH2 Mutations in total: 55/587 (9.4%) cases EZH2 mutated % % 120 EZH2 mutated % EZH2 wt % 6.3% 50.0% 0
19 FIP1L1PDGFRA Fusion Gene in HES/CEL Analysis for FIP1L1PDGFRA was performed in 2039 cases with suspected HES/CEL or unclear eosinophilia nested RTPCR 49/2039 (2.4%) were tested positive
20 Screening for PDGFR Rearrangements Score et al., Leukemia 2006 Erben et al., Haematologica 2009 FIP1L1PDGFRA: 49/2039 (2.4%) ETV6PDGFRB: 3/148 (2.0%) PDGFRA: 2/365 (0.5%) PDGFRB: 7/367 (1.9%) KITD816: 66/294 (22.4%)
21 Konstitutional Mutations untersucht mutiert VHL EPOR 70 0 HIF2A 61 0 PHD2 35 1
22 Workflow MPN Bench et al., BJH, 2012
23 Workflow MPN (MLL) CML BCRABL PV ET PMF 95% 5% 50% 50% 50% 10 % JAK2exon % MPLW515
24 Workflow MPN (MLL) CML BCRABL PV ET PMF 95% 5% 50% 50% 50% 10 % JAK2exon % MPLW515 VHL EPO HIF2A PHD2
25 Workflow MPN (MLL) CML BCRABL PV ET PMF MPN? 95% 5% 50% 50% 50% 50% 50% 10 % JAK2exon % MPLW515 VHL EPO HIF2A PHD2 MPL THPO
26 Workflow MPN (MLL) CML BCRABL PV ET PMF MPN? 95% 5% 50% 50% 50% 50% 50% 10 % JAK2exon % MPLW515 Eosinophilie? VHL EPO HIF2A PHD2 MPL THPO FIP1L1PDGRFA PDGFRA PDGFRB
27 Workflow MPN (MLL) CML BCRABL PV ET PMF MPN? 95% 5% 50% 50% 50% 50% 50% 10 % JAK2exon % MPLW515 Eosinophilie? VHL EPO HIF2A PHD2 MPL THPO FIP1L1PDGRFA PDGFRA PDGFRB KIT Mastocytosis
28 Molecular Genetics in MPN CML BCRABL PV ET PMF MPN? 95% 5% 50% 50% 50% 50% 50% 10 % JAK2exon12 VHL EPO HIF2A PHD2 510 % MPLW515 MPL THPO Eosinophilie? FIP1L1PDGRFA PDGFRA PDGFRB NHL? FGFR KIT Mastocytosis
29 Molecular Genetics in MPN CML BCRABL PV ET PMF MPN? CMML MPN/MDS 95% 5% 50% 50% 50% 50% 50% 90% 10% 10 % JAK2exon12 VHL EPO HIF2A PHD2 510 % MPLW515 MPL THPO Eosinophilie? FIP1L1PDGRFA PDGFRA PDGFRB NHL? FGFR KIT Mastocytosis
30 Workflow MPN (MLL) CML BCRABL PV ET PMF MPN? CMML MPN/MDS 95% 5% 50% 50% 50% 50% 50% 90% 10% 10 % JAK2exon12 VHL EPO HIF2A PHD2 510 % MPLW515 MPL THPO Eosinophilie? PDGFRA PDGFRB NHL? FGFR KIT Mastocytosis CBL 20%
31 Workflow MPN (MLL) CML BCRABL PV ET PMF MPN? CMML MPN/MDS 95% 5% 50% 50% 50% 50% 50% 90% 10% 10 % JAK2exon12 VHL EPO HIF2A PHD2 510 % MPLW515 MPL THPO Eosinophilie? PDGFRA PDGFRB NHL? FGFR KIT Mastocytosis CBL 20% SRSF2 NRAS EZH2 ASXL1 RUNX1 (NPM1) (MLLPTD)
32 Workflow MPN (MLL) CML BCRABL PV ET PMF MPN? CMML MPN/MDS 95% 5% 50% 50% 50% 50% 50% 90% 10% 10 % JAK2exon12 VHL EPO HIF2A PHD2 510 % MPLW515 MPL THPO Eosinophilie? PDGFRA PDGFRB NHL? FGFR KIT Mastocytosis CBL 20% SRSF2 NRAS EZH2 ASXL1 RUNX1 (NPM1) (MLLPTD)
33 Workflow MPN (MLL) CML BCRABL PV ET PMF MPN? CMML MPN/MDS 95% 5% 50% 50% 50% 50% 50% 90% 10% 10 % JAK2exon12 VHL EPO HIF2A PHD2 510 % MPLW515 MPL THPO Eosinophilie? PDGFRA PDGFRB NHL? FGFR KIT Mastocytosis CBL 20% SRSF2 NRAS EZH2 ASXL1 RUNX1 (NPM1) (MLLPTD)
34 Workflow MPN (MLL) CML BCRABL PV ET PMF MPN? CMML MPN/MDS 95% 5% 50% 50% 50% 50% 50% 90% 10% 10 % JAK2exon12 VHL EPO HIF2A PHD2 510 % MPLW515 MPL THPO Eosinophilie? PDGFRA PDGFRB NHL? FGFR KIT Mastocytosis CBL 20% SRSF2 NRAS EZH2 ASXL1 RUNX1 (NPM1) (MLLPTD)
35 Workflow MPN (MLL) CML BCRABL PV ET PMF MPN? CMML MPN/MDS 95% 5% 50% 50% 50% 50% 50% 90% 10% 10 % JAK2exon12 VHL EPO HIF2A PHD2 510 % MPLW515 MPL THPO Eosinophilie? PDGFRA PDGFRB NHL? FGFR KIT Mastocytosis CBL 20% SRSF2 NRAS EZH2 ASXL1 RUNX1 (NPM1) (MLLPTD)
36 SUGGESTION WORKFLOW Schnittger et al, Haematologica, 2012
A Comprehensive Study of TP53 Mutations in Chronic Lymphocytic Leukemia: Analysis of 1,287 Diagnostic CLL Samples
A Comprehensive Study of TP53 Mutations in Chronic Lymphocytic Leukemia: Analysis of 1,287 Diagnostic CLL Samples Sona Pekova, MD., PhD. Chambon Ltd., Laboratory for molecular diagnostics, Prague, Czech
Supplementary Figure 1
Count Count Supplementary Figure 1 Coverage per amplicon for error-corrected sequencing experiments. Errorcorrected consensus sequence (ECCS) coverage was calculated for each of the 568 amplicons in the
SUPPLEMENTARY INFORMATION
doi:10.1038/nature13898 Supplementary Information Table 1 Kras mutation status of carcinogen-induced mouse lung adenomas Tumour Treatment Strain Grade Genotype Kras status (WES)* Kras status (Sanger) 32T1
CBL and EZH2 as new molecular markers in MPN
CBL and EZH2 as new molecular markers in MPN Andy Chase University of Southampton and Wessex Regional Genetics Laboratory Salisbury, UK Munich 2011 * Myeloproliferative neoplasms MDS/MPN Myelodysplastic
Technical Bulletin No. 100
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 100 August 2, 2012 JAK2 AND MPL 515 MUTATIONAL ANALYSIS Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Technical Director, CPAL Jill A.
Welcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM
Welcome to Master Class for Oncologists Session 3: 9:15 AM - 10:00 AM Miami, FL December 18, 2009 Myeloproliferative Neoplasms: Bringing Order to Complexity and Achieving Optimal Outcomes Speaker: Andrew
Should Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!!
Should Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!! Lindsay Anne Magura Rein, MD Division of Hematologic Malignancies and Cellular Therapy/BMT A Little Bit of History.. 1665 Advanced
Diagnostic Approach for Eosinophilia and Mastocytosis. Curtis A. Hanson, M.D.
Diagnostic Approach for Eosinophilia and Mastocytosis Curtis A. Hanson, M.D. 2014 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2014 MFMER slide-2 Molecular Classification
Molecular Diagnostics for Myeloproliferative Neoplasms. Noah Brown, MD April 16, 2015
Molecular Diagnostics for Myeloproliferative Neoplasms Noah Brown, MD April 16, 2015 Outline 1. Brief MPN Introduction 2. When/How Should Molecular Testing be Performed? 3. JAK2 V617F Mutation Testing
Characterization of MPL-mutated myeloid neoplasms: a review of 224 MPL+ cases
Article Characterization of MPL-mutated myeloid neoplasms: a review of 224 MPL+ cases Keming Lin 1,*, Gang Xu 1, Jie-Gen Jiang 1, Mayuko Imai 1, Zhao Wu 1, Paris Petersen 1, Kim Janatpour 1, and Bashar
Introduction of an NGS gene panel into the Haemato-Oncology MPN service
Introduction of an NGS gene panel into the Haemato-Oncology MPN service Dr. Anna Skowronska, Dr Jane Bryon, Dr Samuel Clokie, Dr Yvonne Wallis and Professor Mike Griffiths West Midlands Regional Genetics
Approaching myeloid neoplasms: diagnostic algorithms
Approaching myeloid neoplasms: diagnostic algorithms Alexandar Tzankov Histopathology Pathology Content Integration of clinical and laboratory data Bone marrow evaluation approaching Myeloproliferative
Supporting Information
Supporting Information Rampal et al. 10.1073/pnas.1407792111 Fig. S1. Genetic events in leukemic transformation of chronic-phase MPNs. (A) Survival of post-mpn AML patients according to mutational status
School of Pathology and Laboratory Medicine: Current and New Research Interests
School of Pathology and Laboratory Medicine: Current and New Research Interests W/Professor Wendy Erber Current Research Interests Viral immunology and immunogenetics Bone pathology and cell signalling
Disclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
ex ex ex 12 PHD1 'ex 1-5) ; PHD3 (ex 1-3) ; HIF1 (ex 9, 12, 150) EX EX 3 EX 12 ex ex ex12 HBB, HBA1, HBA2
Hypoxia sensing The following labs explore oxygen sensing pathways and related genes (details about the labs in the second table) Country Name VHL PHD2 HIF2 Others Germany Dr. Schnittger whole P317 and
Fabry Disease X-linked genetic, multi-organ disorder. Fabry disease screening program in Hypertrophic p Cardiomyopathy: preliminary results.
Fabry Disease X-linked genetic, multi-organ disorder Fabry disease screening program in Hypertrophic p Cardiomyopathy: y preliminary results. Globotriaosylceramide, GL3 Brain -galactosidase A Eyes Lactosylceramide
Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ
Illumina Trusight Myeloid Panel validation A R FHAN R A FIQ G E NETIC T E CHNOLOGIST MEDICAL G E NETICS, CARDIFF To Cover Background to the project Choice of panel Validation process Genes on panel, Protocol
Disclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
Published Ahead of Print on June 24, 2012, as doi: /haematol Copyright 2012 Ferrata Storti Foundation.
Published Ahead of Print on June 24, 2012, as doi:10.3324/haematol.2012.065375. Copyright 2012 Ferrata Storti Foundation. Early Release Paper Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative
West Midlands Regional Genetics Laboratory
West Midlands Regional Genetics Laboratory Haemato-oncology service update letter October 2017 Dear colleagues, We are writing to outline the latest developments to our service, aiming to support the management
Ferrata Storti Foundation
Brief Report Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera Susanne Schnittger, 1 Ulrike Bacher, 2 Claudia Haferlach, 1 Thomas Geer, 3 Peter Müller, 4 Johann
Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E,
Supplementary Figure 1. FACS analysis of cells infected with TY93/H5N1 GFP-627E, TY93/H5N1 GFP-627K, or the TY93/H5N1 PB2(588-759) virus library. To establish our GFP- FACS screening platform, we compared
IV Simposio International Sao Paulo Nov Hematologic malignant diseases molecular information, present and future
IV Simposio International Sao Paulo Nov 7 2012 Hematologic malignant diseases molecular information, present and future Dr. rer. nat. Alexander Kohlmann, MLL Munich Leukemia Laboratory Spectrum of Methods
Disclosures. I do not have anything to disclose. Shared Features of MPNs. Overview. Diagnosis and Molecular Monitoring in the
Myeloproliferative Neoplasms: Diagnosis and Molecular Monitoring in the Target Therapy Era C. Cameron Yin, M.D., Ph.D. Department of Hematopathology UT MD Anderson Cancer Center Disclosures I do not have
Next Generation Sequencing in Haematological Malignancy: A European Perspective. Wolfgang Kern, Munich Leukemia Laboratory
Next Generation Sequencing in Haematological Malignancy: A European Perspective Wolfgang Kern, Munich Leukemia Laboratory Diagnostic Methods Cytomorphology Cytogenetics Immunophenotype Histology FISH Molecular
Myeloproliferative Neoplasms: Diagnosis and Molecular Monitoring in the Era of Target Therapy
Myeloproliferative Neoplasms: Diagnosis and Molecular Monitoring in the Era of Target Therapy C. Cameron Yin, M.D., Ph.D. Department of Hematopathology UT MD Anderson Cancer Center Disclosures I do not
Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
modified dye uptake assay including formazan test EC 90 not tested plaque reduction assay
Sauerbrei A, Bohn-Wippert K, Kaspar M, Krumbholz A, Karrasch M, Zell R. 2015. Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes
Le nuove mutazioni oltre JAK2: IDH1/2 e LNK. Dr.ssa Lisa Pieri
Le nuove mutazioni oltre JAK2: IDH1/2 e LNK Dr.ssa Lisa Pieri First report of IDH1 muta5ons in myeloid malignancies: detected by sequencing an AML genome, preferen5ally clustering with intermediate risk
Opportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD
Opportunities for Optimal Testing in the Myeloproliferative Neoplasms Curtis A. Hanson, MD 2013 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-2
SUPPLEMENTARY INFORMATION
Supplementary Information S1 Frequency of DNMT3A mutations in hematologic disorders and their associated clinical phenotypes. Disease Patient population Frequency (%) Associated Clinical Characteristics
TEST MENU TEST CPT CODES TAT. Chromosome Analysis Bone Marrow x 2, 88264, x 3, Days
TEST MENU CANCER/LEUKEMIA CHROMOSOME ANALYSIS Chromosome Analysis Bone Marrow 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome Analysis Bone Marrow Core 88237 x 2, 88264, 88280 x 3, 88291 4 Days Chromosome
Biologia molecolare delle malattie mieloproliferative croniche Ph1-negative tipiche
41 CONGRESSO NAZIONALE SIE Bologna 14-17 Ottobre 2007 Biologia molecolare delle malattie mieloproliferative croniche Ph1-negative tipiche Alessandro M. Vannucchi Dip.. di Ematologia, Università degli Studi
9/25/2017. Disclosure. I have nothing to disclose. Young S. Kim MD Dept. of Pathology
Disclosure MAST CELLNEOPLASM I have nothing to disclose. Young S. Kim MD Dept. of Pathology 1 Objectives What is mast cell lineage? Changes in updated WHO 2016 mastocytosis Issues of Mastocytosis CD30
Presenter Disclosure Information
Welcome to Master Class for Oncologists Session 3: 2: PM 3:3 PM Pasadena, CA May 1, 21 Myeloproliferative Neoplasms 21 Speaker: Ayalew Tefferi Mayo Clinic, Rochester, MN Presenter Disclosure Information
SUPPLEMENTARY INFORMATION. Rare independent mutations in renal salt handling genes contribute to blood pressure variation
SUPPLEMENTARY INFORMATION Rare independent mutations in renal salt handling genes contribute to blood pressure variation Weizhen Ji, Jia Nee Foo, Brian J. O Roak, Hongyu Zhao, Martin G. Larson, David B.
Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms
Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms Version: MPNBiomarkers 1.0.0.2 Protocol Posting Date: June 2017 This biomarker template is NOT required for accreditation
Supplementary Figure 1. Cytoscape bioinformatics toolset was used to create the network of protein-protein interactions between the product of each
Supplementary Figure 1. Cytoscape bioinformatics toolset was used to create the network of protein-protein interactions between the product of each mutated gene and the panel of 125 cancer-driving genes
Session 4: Summary and Conclusions
Session 4: Summary and Conclusions Total cases in Session 4 Myeloproliferative neoplasms 16 cases Oral #300 (CEL, NOS) Mastocytosis 2 cases Oral #156 (SM-AHN) Myeloid/lymphoid neoplasms with eosinophilia
MPL W515L K mutation
MPL W515L K mutation BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
Winship Cancer Institute of Emory University New Determinants and Approaches for MPN
Winship Cancer Institute of Emory University New Determinants and Approaches for MPN Elliott F. Winton August 8, 2014 Sea Island, Georgia Outline: MPN Determinants, Approaches Diagnosis Prognosis Treatment
Disclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
Clinical molecular profiling of archival tumor tissue and cell-free DNA from patients with Erdheim-Chester disease
ECD International Medical Symposium New York City October 26, 2017 Clinical molecular profiling of archival tumor tissue and cell-free DNA from patients with Erdheim-Chester disease Filip Janku, Eli Diamond,
[COMPREHENSIVE GENETIC ASSAY PANEL ON
2014 SN GENELAB AND RESEARCH CENTER DR. SALIL VANIAWALA, PH.D [COMPREHENSIVE GENETIC ASSAY PANEL ON MYELOPROLIFERATIVE NEOPLASMS] SN Genelab presents one of the most comprehensive genetic assay panel for
Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) Updated
Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) Updated Attilio Orazi, MD, FRCPath. (Engl.) Professor of Pathology and Laboratory Medicine Weill Cornell Medical College/NYP Hospital New York, NY
Pathogenesis and management of CMML
Pathogenesis and management of CMML Raphaël Itzykson, Hôpital Saint-Louis, Paris International Conference of the Korean Society of Hematology March 29th 2018 대한혈액학회 Korean Society of Hematology COI disclosure
Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH )
Blastic Plasmacytoid Dendritic Cell Neoplasm with DNMT3A and TET2 mutations (SH2017-0314) Habibe Kurt, Joseph D. Khoury, Carlos E. Bueso-Ramos, Jeffrey L. Jorgensen, Guilin Tang, L. Jeffrey Medeiros, and
Myeloproliferative Neoplasms
Myeloproliferative Neoplasms (MPN and MDS/MPN) Attilio Orazi, MD, FRCPath Weill Cornell Medical College/ NY Presbyterian Hospital, New York, NY USA EAHP EDUCATIONAL SESSION: Updated WHO classification
Current Techniques in Molecular Biology Friedel Nollet, Ph.D.
Current Techniques in Molecular Biology Friedel Nollet, Ph.D. Molecular Biology and Cytometry course May 16-17, 2013 Mol, SCK-CEN, Belgium Sanger DNA sequencing Kary Mullis received a Nobel Prize in chemistry
Leukemia and subsequent solid tumors among patients with myeloproliferative neoplasms
Leukemia and subsequent solid tumors among patients with myeloproliferative neoplasms Tiziano Barbui (tbarbui@asst-pg23.it Hematology and Research Foundation,Ospedale Papa Giovanni XXIII, Bergamo Italy
Genetic complexity in MPN, MDS/MPN and MDS
Genetic complexity in MPN, MDS/MPN and MDS Nick Cross Wessex Regional Genetics Laboratory, Salisbury Faculty of Medicine, University of Southampton Genetic complexity in chronic myeloid neoplasms Classes
The 2008 World Health Organization Classification System for Myeloproliferative Neoplasms
Review Article The 2008 World Health Organization Classification System for Myeloproliferative Neoplasms Order Out of Chaos Ayalew Tefferi, MD 1 ; Juergen Thiele, MD 2 ; and James W. Vardiman, MD 3 The
Out-Patient Billing CPT Codes
Out-Patient Billing CPT Codes Updated Date: August 3, 08 Client Billed Molecular Tests HPV DNA Tissue Testing 8764 No Medicare Billed - Molecular Tests NeoARRAY NeoARRAY SNP/Cytogenetic No 89 NeoLAB NeoLAB
Changing demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
Juvenile and Chronic Myelo-Monocytic Leukemia
Juvenile and Chronic Myelo-Monocytic Leukemia Haematopoietic stem cell Lympho-myeloid progenitor cell MEP CFU-GM lymphoid progenitor cell BFU-E CFU-MK CFU-E erythro CFU-M CFU-G CFU-T CFU-B MGK red blood
Disclosures for Angela Fleischman
Disclosures for Angela Fleischman Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Sierra, Incyte None None None Incyte None Presentation includes
WHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities
WHO Classification of Myeloid Neoplasms with Defined Molecular Abnormalities Robert W. McKenna, M.D. 1/2009 WHO Classification of Myeloid Neoplasms (4th Edition)--2008 Incorporates new information that
SH A CASE OF PERSISTANT NEUTROPHILIA: BCR-ABL
SH2017-0124 A CASE OF PERSISTANT NEUTROPHILIA: BCR-ABL NEGATIVE John R Goodlad 1, Pedro Martin-Cabrera 2, Catherine Cargo 2 1. Department of Pathology, NHS Greater Glasgow & Clyde, QEUH, Glasgow 2. Haematological
Disclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
Prognostic models in PV and ET
Prognostic models in PV and ET Francesco Passamonti Hematology, Varese, Italy Current risk stratification in PV and ET: statement from European LeukemiaNet consensus Age over 60 years Previuos thrombosis
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia
Concomitant WT1 mutations predicted poor prognosis in CEBPA double-mutated acute myeloid leukemia Feng-Ming Tien, Hsin-An Hou, Jih-Luh Tang, Yuan-Yeh Kuo, Chien-Yuan Chen, Cheng-Hong Tsai, Ming Yao, Chi-Cheng
JAK2 V617F analysis. Indication: monitoring of therapy
JAK2 V617F analysis BCR-ABL genotyping The exact chromosomal defect in Philadelphia chromosome is a translocation. Parts of two chromosomes, 9 and 22, switch places. The result is a fusion gene, created
"Calreticulin Mutation Analysis in Iranian patients suffering from Essential thrombocythemia and Primary Myelofibrosis
"Calreticulin Mutation Analysis in Iranian patients suffering from Essential thrombocythemia and Primary Myelofibrosis Dr Behzad Poopak, DCLS PhD. Associate professor of fhematology Islamic Azad University
Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms
Template for Reporting Results of Biomarker Testing for Myeloproliferative Neoplasms Template web posting date: December 2014 Authors Todd W. Kelley, MD, FCAP University of Utah and ARUP Laboratories,
MYELOPROLIFERATIVE NEOPLASMS
9 : 2 MYELOPROLIFERATIVE NEOPLASMS Introduction William Dameshek in 1951 introduced the term Myeloproliferative disorders (MPD). This included polycythemia vera (PV), essential thrombocythemia (ET), primary
Next generation histopathological diagnosis for precision medicine in solid cancers
Next generation histopathological diagnosis for precision medicine in solid cancers from genomics to clinical application Aldo Scarpa ARC-NET Applied Research on Cancer Department of Pathology and Diagnostics
Supplemental Material. The new provisional WHO entity RUNX1 mutated AML shows specific genetics without prognostic influence of dysplasia
Supplemental Material The new provisional WHO entity RUNX1 mutated AML shows specific genetics without prognostic influence of dysplasia Torsten Haferlach, 1 Anna Stengel, 1 Sandra Eckstein, 1 Karolína
Sample Metrics. Allele Frequency (%) Read Depth Ploidy. Gene CDS Effect Protein Effect. LN Metastasis Tumor Purity Computational Pathology 80% 60%
Supplemental Table 1: Estimated tumor purity, allele frequency, and independent read depth for all gene mutations classified as either potentially pathogenic or VUS in the metatastic and primary tumor
Personalized Healthcare Update
Dr. Kai - Oliver Wesche Market Development Manager, Personalized Healthcare QIAGEN Personalized Healthcare Update Pioneering Personalized Medicine through Partnering TOMTOVOK BKM120 Zelboraf QIAGEN partners:
Myeloproliferative neoplasms: recent advances in pathogenesis
Myeloproliferative neoplasms: recent advances in pathogenesis Andy Chase University of Southampton and Wessex Regional Genetics Laboratory Salisbury, UK Uppsala 2010 Myeloproliferative neoplasms MDS/MN
WHO Update to Myeloproliferative Neoplasms
WHO Update to Myeloproliferative Neoplasms Archana M Agarwal, MD, Associate Professor of Pathology University of Utah Department of Pathology/ARUP Laboratories Myeloproliferative Neoplasms The categories
ASBMT MDS/MPN Update Sunil Abhyankar, MD
ASBMT MDS/MPN Update Sunil Abhyankar, MD Professor of Medicine Medical Director, Pheresis and Cell Processing Division of Hematologic Malignancies and Cellular Therapeutics Department of Internal Medicine
August 17, Dear Valued Client:
August 7, 08 Re: CMS Announces 6-Month Period of Enforcement Discretion for Laboratory Date of Service Exception Policy Under the Medicare Clinical Laboratory Fee Schedule (the 4 Day Rule ) Dear Valued
CURRENT MOLECULAR DIAGNOSTICS IN HEMATOONCOLOGY
Third Slovenian congress of hematology and transfusion medicne, Podcetrtek, April 08 Third Slovenian congress of hematology and transfusion medicne, Podcetrtek, April 08 CURRENT MOLECULAR DIAGNOSTICS IN
WHO Classification 7/2/2009
Least Malignant Myeloproliferative Disorders Myelodysplastic Syndromes Most Malignant Acute Leukemia Classifying Hematopoietic Disorders French-American-British (FAB) World Health Organization (WHO) Thanks
Please Silence Your Cell Phones. Thank You
Please Silence Your Cell Phones Thank You Utility of NGS and Comprehensive Genomic Profiling in Hematopathology Practice Maria E. Arcila M.D. Memorial Sloan Kettering Cancer Center New York, NY Disclosure
SESSION III: Chronic myeloid leukemia PONATINIB. Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy
SESSION III: Chronic myeloid leukemia PONATINIB Gianantonio Rosti, MD, Department of Hematology, University of Bologna, Italy Ponatinib A Pan-BCR-ABL Inhibitor Rationally designed inhibitor of BCR- ABL
The Challenges of Precision Medicine: New Advances in Molecular Diagnostic Testing- Impact for Healthcare
The Challenges of Precision Medicine: New Advances in Molecular Diagnostic Testing- Impact for Healthcare Jessica Wang-Rodriguez, MD Chief, VISN22 Consolidated Pathology and Laboratory Medicine Services
Clinical Utility of Droplet ddpcr, moving to diagnostics. Koen De Gelas, PhD, CRIG ddpcr mini symposium, 15/05/2018
1 Clinical Utility of Droplet ddpcr, moving to diagnostics 2 Koen De Gelas, PhD, CRIG ddpcr mini symposium, 15/05/2018 Disclaimer Disclaimer: all consumables, instruments, applications and software covered
Precision Medicine and Molecular Testing.
Precision Medicine and Molecular Testing. David A. Sallman, MD Assistant Member Department of Malignant Hematology Moffitt Cancer Center david.sallman@moffitt.org Disclosures Research funding for Celgene
JAK2 Inhibitors for Myeloproliferative Diseases
JAK2 Inhibitors for Myeloproliferative Diseases Srdan (Serge) Verstovsek M.D., Ph.D. Associate Professor Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Myeloproliferative
Mielofibrosi: inquadramento dei fattori prognostici
Mielofibrosi: inquadramento dei fattori prognostici Francesco Passamon, Division of Hematology University Hospital, Fondazione Macchi Varese, Italy Reduced survival in PMF and causes of death Median OS
Meccanismi molecolari di progressione di mala0a nelle neoplasie mieloprolifera2ve croniche PAOLA GUGLIELMELLI
Meccanismi molecolari di progressione di mala0a nelle neoplasie mieloprolifera2ve croniche PAOLA GUGLIELMELLI Sez. di Ematologia Università di Firenze Leukemic Transforma2on in MPN MPN subtype Essen2al
Case Presentation. Attilio Orazi, MD
Case Presentation Attilio Orazi, MD Weill Cornell Medical College/ NYP Hospital Department of Pathology and Laboratory Medicine New York, NY United States History 60 year old man presented with anemia
Hypereosinophili c syndrome
Hypereosinophili c syndrome Eosinophilia Eosinophilia is commonly defined as an elevated percentage of eosinophils, with an absolute eosinophil count > 500 cells per cubic millimeter Secondary Primary
Cost-Effective Strategies in the Workup of Hematologic Neoplasm. Karl S. Theil, Claudiu V. Cotta Cleveland Clinic
Cost-Effective Strategies in the Workup of Hematologic Neoplasm Karl S. Theil, Claudiu V. Cotta Cleveland Clinic In the past 12 months, we have not had a significant financial interest or other relationship
The Center for PERSONALIZED DIAGNOSTICS
The Center for PERSONALIZED DIAGNOSTICS Precision Diagnostics for Personalized Medicine A joint initiative between The Department of Pathology and Laboratory Medicine & The Abramson Cancer Center The (CPD)
Targeted NGS in oncology and hemato-oncology using in-house designed gene panels. Joni Van der Meulen Molecular Diagnostics UZ Ghent (MDG) 24/03/2017
Targeted NGS in oncology and hemato-oncology using in-house designed gene panels Joni Van der Meulen Molecular Diagnostics UZ Ghent (MDG) 24/03/2017 MDG = Molecular Diagnostics UZ Ghent Center for Medical
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study. February 2018
Targeted Agent and Profiling Utilization Registry (TAPUR ) Study February 2018 Precision Medicine Therapies designed to target the molecular alteration that aids cancer development 30 TARGET gene alterations
Vertical Magnetic Separation of Circulating Tumor Cells and Somatic Genomic-Alteration Analysis in Lung Cancer Patients
Vertical Magnetic Separation of Circulating Cells and Somatic Genomic-Alteration Analysis in Lung Cancer Patients Chang Eun Yoo 1,2#, Jong-Myeon Park 3#, Hui-Sung Moon 1,2, Je-Gun Joung 2, Dae-Soon Son
Cooperation of germ line JAK2 mutations E846D and R1063H leads to erythroid hyperplasia with megakaryocytic atypia
Cooperation of germ line JAK2 mutations E846D and R1063H leads to erythroid hyperplasia with megakaryocytic atypia Katarina Kapralova, Ph.D. Department of Biology Faculty of Medicine and Dentistry Palacký
Disclosure: Objectives/Outline. Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations. Nothing to disclose.
RC1 Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations RC2 Disclosure: Nothing to disclose Henry Moon Lecture: UCSF Annual Conference Kathryn Foucar, MD kfoucar@salud.unm.edu May
Changing AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight
Changing AML Outcomes via Personalized Medicine: Transforming Cancer Management with Genetic Insight Co-Moderators: Rick Winneker, PhD, Senior Vice President, Research, Leukemia & Lymphoma Society Mike
Update on Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Kaaren Reichard Mayo Clinic Rochester
Update on Myelodysplastic Syndromes and Myeloproliferative Neoplasms Kaaren Reichard Mayo Clinic Rochester Reichard.kaaren@mayo.edu Nothing to disclose Conflict of Interest Learning Objectives Present
WHO 2016/17 update on Myeloproliferative Neoplasms. Anna Ruskova Auckland City Hospital New Zealand
WHO 2016/17 update on Myeloproliferative Neoplasms Anna Ruskova Auckland City Hospital New Zealand BLOOD, 19 MAY 2016 x VOLUME 127, NUMBER 20 2 2016/17 Classification of Myeloproliferative Neoplasms Chronic
Genetic Analysis of Allosteric Signaling in RhaR from Escherichia coli and Characterization of the VirF Protein from Shigella flexneri
Genetic Analysis of Allosteric Signaling in RhaR from Escherichia coli and Characterization of the VirF Protein from Shigella flexneri By Bria Collette Kettle Submitted to the graduate degree program in